Immunospot.eu

Cellular Technology Limited (CTL), widely known by its brand name ImmunoSpot, is a biotechnology company specializing in the development and provision of ELISPOT and FluoroSpot technology. The company offers a comprehensive ecosystem for immune monitoring, including high-resolution imaging analyzers, standardized assay kits, and specialized reagents. CTL's platform is a gold standard for quantifying antigen-specific T cell and B cell responses at the single-cell level, supporting research in vaccine development, oncology, and infectious diseases. Additionally, the company provides contract research services (CRO) and maintains an extensive library of cryopreserved human peripheral blood mononuclear cells (PBMCs) for standardized testing. Headquartered in Ohio with a significant presence in Europe, CTL was acquired by Antylia Scientific in 2022 to further expand its reach in the life sciences sector.